Valisure is a start-up company founded in 2015 in New Haven, CT by a group of Yale and Harvard alumni with proven biotech industry success (recent exit: Ion Torrent $725M). Valisure’s disruptive […]
Alexandra Barnes
CancerVacs’ Antigens Activate Anti-Tumor Immunity
CancerVacs is developing intralymphnode immunotherapeutics for certain metastatic cancer patients with no therapeutic options. This includes disseminated follicular lymphoma, glioblastoma multiforme, metastatic castrate-resistant prostate carcinoma, malignant melanoma, or other metastatic solid tumor. […]
Dr. Amit Vohra – Promaxo’s MRI for Prostate Cancer Diagnosis
Dr. Amit Vohra is the founder & CEO of Promaxo, a company tackling prostate disease management through the development of an office-based MRI. Brett Johnson interviewed Dr. Vohra to find out in […]
OncoTAb awarded National Cancer Institute contract for breast cancer therapy
OncoTAb, Inc. announced that the company was named as a recipient of a $300,000 grant by the National Cancer Institute (NCI) to begin pre-clinical development of a targeted therapy for triple negative breast […]
Offshore Fund Seeks Investment in Small Micro Cap Companies
Offshore Fund Seeks Investment in Small Micro Cap Companies Using Equity Financing Structure Investment Criteria: $1+ share price…lower stock price considered depending on liquidity, business model, management team, etc. Investment Size: generally $1 […]
Promaxo’s Portable MRI
Promaxo, a medical device startup focusing on portable MRI and other technology, is developing and commercializing an office-based, portable MRI with cellular level spatial resolution. Also in development is a real time […]
Anavex Signs Material Transfer Agreement with Biogen
Anavex Life Sciences Corp. announced the signing of a material transfer agreement with Biogen, wherein Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell, OPC, differentiation assay. A satisfactory result […]
Tactical Therapeutics Presents Trial Results for Glioblastoma Treatment
Tactical Therapeutics, Inc., an emerging growth oncology drug development company, presented results of two Phase IB trials of its lead drug Carboxyamidotriazole Orotate (CTO, PRAVITNIB) at the American Society of Clinical Oncology […]
